PSTV
Plus Therapeutics, Inc.NASDAQHealthcare$3.56-6.46%ClosedMarket Cap: $8.6M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
2.59
P/S
1.55
EV/EBITDA
-0.01
DCF Value
$0.62
FCF Yield
-258.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
91.5%
Operating Margin
-293.5%
Net Margin
-429.4%
ROE
774.8%
ROA
-137.1%
ROIC
-317.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $1.4M | 93.3% | $-5.7M | $-5.7M | $-0.04 | — |
| FY 2025 | $5.2M | 91.5% | $-15.3M | $-22.4M | $-0.29 | — |
| Q3 2025 | $1.4M | 93.8% | $-4.5M | $-4.4M | $-1,000.00 | — |
| Q2 2025 | $1.4M | 93.8% | $-1.5M | $5.2M | $-162.50 | — |
| Q1 2025 | $1.1M | 82.9% | $-3.5M | $-17.4M | $-29,750.00 | — |
| Q4 2024 | $1.4M | 83.6% | $-3.9M | $-3.9M | $-16,500.00 | — |
| FY 2024 | $5.8M | 85.4% | $-14.7M | $-13.0M | $-58,500.00 | — |
| Q3 2024 | $1.5M | 84.1% | $-3.8M | $-2.9M | $-9,250.00 | — |
| Q2 2024 | $1.3M | 84.2% | $-3.7M | $-2.9M | $-6,750.00 | — |
| Q1 2024 | $1.7M | 88.9% | $-3.3M | $-3.3M | $-18,750.00 | — |
| Q4 2023 | $1.3M | 86.1% | $-3.9M | $-3.8M | $-21,250.00 | — |
| FY 2023 | $4.9M | -97.2% | $-13.3M | $-13.3M | $-106,000.00 | — |